Free Trial
NASDAQ:BCAX

Bicara Therapeutics (BCAX) Stock Price, News & Analysis

Bicara Therapeutics logo
$9.07 -0.13 (-1.37%)
As of 01:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Bicara Therapeutics Stock (NASDAQ:BCAX)

Key Stats

Today's Range
$8.85
$9.43
50-Day Range
$8.71
$15.66
52-Week Range
$7.80
$28.09
Volume
248,783 shs
Average Volume
601,182 shs
Market Capitalization
$494.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.86
Consensus Rating
Buy

Company Overview

Bicara Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
28th Percentile Overall Score

BCAX MarketRank™: 

Bicara Therapeutics scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bicara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Bicara Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Bicara Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Bicara Therapeutics are expected to grow in the coming year, from ($2.59) to ($1.74) per share.

  • Price to Book Value per Share Ratio

    Bicara Therapeutics has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Bicara Therapeutics' valuation and earnings.
  • Short Interest

    There is no current short interest data available for BCAX.
  • Dividend Yield

    Bicara Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Bicara Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for BCAX.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Bicara Therapeutics this week, compared to 4 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Bicara Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    15.50% of the stock of Bicara Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Bicara Therapeutics' insider trading history.
Receive BCAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCAX Stock News Headlines

The $15 Gold Fund That Pays Up to $1,152/Month
Gold prices are breaking records. But while everyone else is fixated on headlines… They're missing something much bigger: There's a new way to collect income from gold.
BCAX Bicara Therapeutics Inc.
See More Headlines

BCAX Stock Analysis - Frequently Asked Questions

Bicara Therapeutics' stock was trading at $17.42 at the start of the year. Since then, BCAX shares have decreased by 47.9% and is now trading at $9.0740.
View the best growth stocks for 2025 here
.

Bicara Therapeutics Inc. (NASDAQ:BCAX) posted its earnings results on Tuesday, May, 13th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.28.

Bicara Therapeutics (BCAX) raised $315 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 17,500,000 shares at a price of $18.00 per share.

Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/13/2025
Today
7/03/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BCAX
Previous Symbol
NASDAQ:BCAX
Fax
N/A
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.86
High Stock Price Target
$48.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+246.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$9.04 per share
Price / Book
1.02

Miscellaneous

Free Float
46,083,000
Market Cap
$501.77 million
Optionable
N/A
Beta
N/A
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:BCAX) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners